MILAN, Italy, June 4th, 2007 - Brane Discovery Srl, a newly formed specialty pharmaceutical company focused on the development of novel CNS therapies, today announced the acquisition of a pre-clinical program targeting the Opioid Receptor Like-1 (ORL-1) from Nikem Research, who acquired ORL-1 from GlaxoSmithKline (GSK). The ORL-1 program originates in the 2003 research and development collaboration agreement GSK entered into with NiKem Research to discover novel modulators for the ORL-1 receptor. This antagonist program, which has already generated a preclinical candidate (BND-001), will now enter the broad preclinical CNS focused pipeline of Brane Discovery. Brane was spun out of NiKem Research in April 2007.
